Treatment of congenital hypogonadotropic hypogonadism in male patients
- Author:
Hae Sang LEE
1
;
Young Suk SHIM
;
Jin Soon HWANG
Author Information
- Publication Type:Review Article
- From:Annals of Pediatric Endocrinology & Metabolism 2022;27(3):176-182
- CountryRepublic of Korea
- Language:English
- Abstract: Congenital hypogonadotropic hypogonadism (CHH) is characterized by complete or partial failure of pubertal development because of inadequate secretion of gonadotropic hormones. CHH consists of hypogonadotropic hypogonadism with anosmia or hyposmia, Kallmann syndrome, and the normosmic variation normosmic idiopathic hypogonadotropic hypogonadism. CHH is one of the few treatable diseases of male infertility, although men with primary testicular dysfunction have irreversibly diminished spermatogenic capacity. The approach to CHH treatment is determined by goals such as developing virilization or inducing fertility. This review focuses on the current knowledge of therapeutic modalities for inducing puberty and fertility in men with CHH.
